PROF Ashley Bush

PROF Ashley Bush


  • Alzheimer's disease (metals, oxidative stress, iron, diagnostics, therapeutics)
  • Motor Neurone Disease (Copper, therapeutics)
  • Parkinson's Disease (therapeutics, iron)



  • Ashley Bush (MBBS, DPM, FRANZCP, PhD, FAAHMS, FAPA), NHMRC Senior Principal Research Fellow is the Director of the Melbourne Dementia Research Centre and Head of the Oxidation Biology Unit at The Florey Institute of Neuroscience & Mental Health, University of Melbourne. He has made outstanding contributions to the neuroscience field, most notably his discovery of the importance of metal biology in neurodegenerative brain diseases. The impact of his work has moved the field of neurodegeneration towards an appreciation for an underlying disturbance in brain metal homeostasis, and has provided insights into the pathogenesis of Alzheimer’s disease (AD) as well as other brain diseases including amyotrophic lateral sclerosis, Parkinson’s and Huntington’s diseases. His leadership has led to the development of new predictive tests for AD and innovative, potentially disease-modifying strategies based on his research. He is Chief Scientific Officer for the Cooperative Research Centre for Mental Health (Parkville) and Co-Director of Biomarker Development for The Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL). He is Professor of Neuroscience and Psychiatry at the University of Melbourne, and holds courtesy staff appointments in Psychiatry and Radiology at Massachusetts General Hospital, USA. He is Founding Scientist of Prana Biotechnology Ltd, Cogstate Ltd, and Chief Scientific Officer for Collaborative Medicinal Development P/L. As a recognised expert in his field, Prof Bush has published 451 publications (>42,000 citations) and 28 patents, is ad hoc reviewer of 48 journals, and has delivered over 320 invited lectures (including 207 international and 25 Plenary). Prof Bush is one of the most highly cited neuroscientists in Australia, is rated in the top 1% of neuroscience researchers worldwide for high impact citations (2014-2016, 2018), and classed as one of the World's Most Influential Scientific Minds (Thomson Reuters & Clarivate Analytics).   


Member of

  • American Psychiatric Association. Member 2015 -
  • Australian Academy of Health & Medical Sciences. Fellow 2015 -
  • Australasian Neuroscience Society Inc. Member 2014 -
  • Australian Translational Psychiatry Consortium. Member 2014 -
  • veski connection. Member ( 2014 -
  • International Society for Neurochemistry. Member 2011 -
  • Australian Academy of Technological Sciences & Engineering. Fellow 2009 -
  • The American Society for Biochemistry and Molecular Biology. Member 2003 -
  • American Medical Association. Member 1995 -
  • American Association for the Advancement of Science. Member 1993 -
  • Society for Neuroscience. Member 1993 -
  • Royal Australian and New Zealand College of Psychiatrists. Fellow 1989 -


Selected publications


Investigator on

Additional Grant Information

  • 01/01/2016-31/12/2020, CIA, NHMRC, Senior Principal Research Fellowship (SPRF), Brain metal neurochemistry: mechanism-driven drug discovery for neurodegeneration, $851,980 09/01/2016 – 05/31/2021, Co-PI, National Institute on Aging Research Project Grant, Neuropathologic-epidemiological study of metallomics and Alzheimer's disease, $1,175,342; 01/01/2018-31/12/2022, CIA, NHMRC Program Grant, Biomarkers to aid clinical trials for neurodegenerative disease, $13,179,875; April 2017-Oct 2019, CIB, Cure for MND Foundation Research Grant, Targeting a deregulated copper-iron axis to treat sporadic MND: A combination treatment strategy, $962,400; 2018-2019, Co-PI, U.S. Department of Defense Health Program Grant (Alzheimer’s Research), Iron dyshomeostasis following brain injury: a novel mechanism for the development of Alzheimer-like neuropathology and associated functional decline, $650,000; 2019-2022, CIB, Dementia Australia Research Foundation (DARF) and The Yulgilbar Foundation Innovation Grant, Nanotechnology for the diagnosis and treatment of neurodegenerative disorders, $1,032,924; 2019-2023, CI, Australian Government Medical Research Future Fund (MRFF) Research Grant, Evaluating the effectiveness and safety of sodium selenate as a disease modifying treatment for patients with behavioural variant Frontotemporal Dementia (bvFTD), $1,604,184.    


Education and training

  • PhD, University of Melbourne 1993
  • DPM, University of Melbourne 1988
  • MBBS, University of Melbourne 1982

Awards and honors

  • Clarivate Analytics, 2018
  • World's Most Influential Scientific Minds, Thomson Reuters, 2016
  • Victoria Prize for Science & Innovation, Veski & Victorian Government, 2014
  • Schering-Plough Senior Research Award, The Royal Australian and New Zealand College of Psychiatrists, 2010
  • Fellow of the Australian Academy of Technological Sciences and Engineering, 2009
  • Award in Neurology, Bethlehem Griffiths Research Foundation, 2007
  • Federation Fellowship, Australian Research Council, 2004
  • Fellow of the Royal Australian and New Zealand College of Psychiatrists, 2004
  • Zenith Fellowship, Alzheimer's Association, 2004
  • Potamkin Prize, American Academy of Neurology, 2003
  • Senator Mark A. Hatfield Award for Clinical Research in Alzheimer's Disease, Alzheimer's Association, 2000
  • Paul Beeson Physician Faculty Scholar in Aging, AFAR, 1998
  • Ellison Scholarship, Massachusetts General Hospital, 1995
  • Scholars Award, National Down Syndrome Society, 1994
  • Organon Award for Psychiatric Research, The Royal Australian and New Zealand College of Psychiatry, 1994
  • Harkness Fellowship, Commonwealth Fund of New York, 1992



Available for supervision

  • Y

Supervision Statement

  • As a recognized expert in my field, having published 451 papers (~42,000 citations) and 28 patents, I have made valuable contributions to the field of neuroscience, most notably my discovery of the importance of metal biology in neurodegenerative brain diseases. Student Mentoring: 13 Doctoral completions; currently supervising 10 PhD students and mentoring 10+postdoctoral and research scientists (including researchers from Israel, China, Germany, and Chile).